Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer is a research paper published in Annals of Surgical Oncology (2023). On theSindex it has a DataRank of 0.464. It has been cited 21 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: U10CA180821
National Cancer Institute
Grant: U10CA180858
National Cancer Institute
Grant: U10CA180870
National Cancer Institute
Grant: U10CA180882
National Cancer Institute
Grant: U24CA196171
National Cancer Institute
Grant: UG1CA232760
National Institutes of Health
Grant: 3U24CA196171-04S1
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
National Institutes of Health
Grant: 5U10CA180858-04
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
National Institutes of Health
Grant: 3UG1CA232760-06S1
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)
National Institutes of Health
Grant: 5U10CA180870-04
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
National Institutes of Health
Grant: 5U10CA180882-02
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
FWCI
2.37
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals